PhaseV
PhaseV is a Boston-based technology company founded in 2023 that specializes in optimizing clinical development for biopharma sponsors and contract research organizations (CROs) through an AI/ML-driven platform. The company aims to enhance the clinical trial industry by accelerating the delivery of new treatments to patients while improving efficiency and precision. The core of PhaseV's offering is its AI Conductor platform, which automates various stages of the clinical trial process, from protocol drafting to final report submission. This platform includes tools like the Trial Optimizer and advanced causal machine learning algorithms, which help refine trial endpoints and streamline operational workflows. PhaseV serves over 30 global pharmaceutical companies and CROs across more than 20 therapeutic areas, including oncology and neurology. The company operates on a B2B model, providing subscription-based SaaS and consulting services to its clients.